Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Hepatol.

Title: Journal of hepatology

Publisher: Elsevier BV

ISSN (Electronic): 1600-0641

ISSN (Print): 0168-8278

Publication date (Electronic): Aug 2017

Volume: 67

Issue: 2

Affiliations

[1 ] Stanford University Division of Gastroenterology and Hepatology, Palo Alto, CA, USA. Electronic address: pkwo@stanford.edu.

[2 ] Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA.

[3 ] AbbVie Inc., North Chicago, Illinois, USA.

[4 ] University of Colorado School of Medicine, Denver, Colorado, USA.

[5 ] Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, USA.

[6 ] Private Practice, Bakersfield, California, USA.

[7 ] Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

[8 ] University of Auckland, Auckland, New Zealand.

[9 ] University of Rochester Medical Center, Rochester, New York, USA.

[10 ] eStudySite, San Diego, California, USA.

[11 ] Henry Ford Health System, Detroit, Michigan, USA.

[12 ] Duke University School of Medicine, Durham, NC, USA.

[13 ] Louisiana Research Center, Shreveport, LA, USA.

[14 ] Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.

[15 ] Kirby Institute, UNSW Sydney, and St. Vincent's Hospital, Sydney, NSW, Australia.

Article

Publisher Item ID: S0168-8278(17)30211-8

DOI: 10.1016/j.jhep.2017.03.039

PubMed ID: 28412293

SO-VID: 7e7294d0-0d05-46f2-b993-430273feadfc

History

Keywords: ABT-493,ABT-530,D-alanine transaminase,Direct-acting antiviral,Genotype,Hepatitis C, chronic,Interferons,Liver cirrhosis,Pangenotypic,SURVEYOR,Sustained virologic response

Data availability:

Keywords: ABT-493, ABT-530, D-alanine transaminase, Direct-acting antiviral, Genotype, Hepatitis C, chronic, Interferons, Liver cirrhosis, Pangenotypic, SURVEYOR, Sustained virologic response

Comments

Comment on this article

Cited by 100

See all cited by